Alnylam Pharmaceuticals, Inc. (ALNY) — Form 10-Q: Quarterly report

Alnylam Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The company discussed its financial condition, ongoing commercial operations, and potential risks associated with its product pipeline and commercial products like AMVUTTRA. Management and the Chief Financial Officer evaluated disclosure controls and procedures and concluded they were effective as of September 30, 2026.